BVAXF (BioVaxys Technology) FCF Margin % : 0.00% (As of Jan. 2025)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioVaxys Technology's Free Cash Flow for the three months ended in Jan. 2025 was $-0.62 Mil. BioVaxys Technology's Revenue for the three months ended in Jan. 2025 was $0.00 Mil. Therefore, BioVaxys Technology's FCF Margin % for the quarter that ended in Jan. 2025 was 0.00%.

As of today, BioVaxys Technology's current FCF Yield % is -19.65%.

The historical rank and industry rank for BioVaxys Technology's FCF Margin % or its related term are showing as below:

BVAXF's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -125.86
* Ranked among companies with meaningful FCF Margin % only.

BioVaxys Technology FCF Margin % Historical Data

The historical data trend for BioVaxys Technology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology FCF Margin % Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

FCF Margin %

Get a 7-Day Free Trial

BioVaxys Technology Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BioVaxys Technology's FCF Margin %

For the Biotechnology subindustry, BioVaxys Technology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVaxys Technology's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's FCF Margin % falls into.

Save Embed

;

Save Embed

;

BioVaxys Technology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BioVaxys Technology's FCF Margin for the fiscal year that ended in Oct. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Oct. 2024 )	/	Revenue (A: Oct. 2024 )
	=	-2.121	/	0
	=	%

BioVaxys Technology's FCF Margin for the quarter that ended in Jan. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jan. 2025 )	/	Revenue (Q: Jan. 2025 )
	=	-0.621	/	0
	=	%

BioVaxys Technology FCF Margin % Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.